A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/19 (2006.01)
Patent
CA 2543319
The present invention relates to methods of treating cancers, e.g., leukemia. More specifically, the present invention relates to methods of treating acute and chronic leukemias including Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic leukemia (CLL), Chronic myeloid leukemia (CML) and Hairy Cell Leukemia, by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blond levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
La présente invention concerne des procédés permettant de traiter des cancers, et notamment la leucémie. L'invention concerne plus particulièrement le traitement de leucémies aiguës et chroniques telles que la leucémie lymphoïde aiguë, de la leucémie myéloïde aiguë, de la leucémie lymphoïde chronique et de la leucémie myéloïde chronique. Un tel traitement nécessite l'administration de compositions pharmaceutiques comprenant des inhibiteurs de l'histone déacétylase (HDAC) tels que l'acide hydroxamique suberoylanilide (SAHA). Les formulations orales de ces compositions pharmaceutiques présentent des profils pharmacocinétiques favorables tels qu'une bio-disponibilité élevée, et une persistance importante, à niveau élevé et de façon prolongée, des composés actifs dans le sang. L'invention concerne également une posologie quotidienne sans risques de ces compositions pharmaceutiques, facile à suivre, et qui donne in vivo une quantité thérapeutiquement efficace d'inhibiteurs de la HDAC.
Bacopoulos Nicholas G.
Chiao Judy H.
Miller Thomas A.
Paradise Carolyn M.
Richon Victoria M.
Aton Pharma Inc.
Merck Hdac Research Llc
Ridout & Maybee Llp
LandOfFree
Methods of treating leukemia with suberoylanilide hydroxamic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating leukemia with suberoylanilide hydroxamic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating leukemia with suberoylanilide hydroxamic... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1718077